ROS 1阳性晚期非小细胞肺癌患者对克唑替尼的特殊长期反应。

IF 0.8 Q4 RESPIRATORY SYSTEM Respirology Case Reports Pub Date : 2024-09-24 eCollection Date: 2024-09-01 DOI:10.1002/rcr2.70033

Anjali Murali, Anju Farsana A, Sobha Subramaniam, Malini Eapen, Indu R Nair, Keechilat Pavithran

{"title":"ROS 1阳性晚期非小细胞肺癌患者对克唑替尼的特殊长期反应。","authors":"Anjali Murali, Anju Farsana A, Sobha Subramaniam, Malini Eapen, Indu R Nair, Keechilat Pavithran","doi":"10.1002/rcr2.70033","DOIUrl":null,"url":null,"abstract":"Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Here, we present the case of a 52-year-old man diagnosed with advanced NSCLC harbouring the ROS1 fusion gene. Despite the initial poor response to conventional chemotherapy, the patient exhibited an exceptional and sustained response to crizotinib, with a progression-free survival of 94 months and complete metabolic response on PET scan. This case underscores the importance of molecular profiling in guiding treatment decisions and highlights the efficacy of targeted therapies for ROS1-positive NSCLC.","PeriodicalId":45846,"journal":{"name":"Respirology Case Reports","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421889/pdf/","citationCount":"0","resultStr":"{\"title\":\"Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer.\",\"authors\":\"Anjali Murali, Anju Farsana A, Sobha Subramaniam, Malini Eapen, Indu R Nair, Keechilat Pavithran\",\"doi\":\"10.1002/rcr2.70033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Here, we present the case of a 52-year-old man diagnosed with advanced NSCLC harbouring the ROS1 fusion gene. Despite the initial poor response to conventional chemotherapy, the patient exhibited an exceptional and sustained response to crizotinib, with a progression-free survival of 94 months and complete metabolic response on PET scan. This case underscores the importance of molecular profiling in guiding treatment decisions and highlights the efficacy of targeted therapies for ROS1-positive NSCLC.\",\"PeriodicalId\":45846,\"journal\":{\"name\":\"Respirology Case Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421889/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respirology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/rcr2.70033\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/rcr2.70033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

摘要

非小细胞肺癌（NSCLC）占全球肺癌病例的大多数，其中相当一部分患者存在可操作的致癌基因改变。在这些改变中，ROS1重排是具有治疗意义的一个独特子集。在此，我们介绍了一名 52 岁男性的病例，他被诊断为携带 ROS1 融合基因的晚期 NSCLC。尽管最初对常规化疗反应不佳，但患者对克唑替尼表现出了卓越而持续的反应，无进展生存期长达 94 个月，PET 扫描显示完全代谢反应。该病例强调了分子谱分析在指导治疗决策方面的重要性，并突出了靶向疗法对ROS1阳性NSCLC的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Exceptional long term response to crizotinib in ROS 1-postive advanced non small cell lung cancer.

Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer cases worldwide, with a significant proportion of patients harbouring actionable oncogenic alterations. Among these alterations, the ROS1 rearrangement represents a distinct subset with therapeutic implications. Here, we present the case of a 52-year-old man diagnosed with advanced NSCLC harbouring the ROS1 fusion gene. Despite the initial poor response to conventional chemotherapy, the patient exhibited an exceptional and sustained response to crizotinib, with a progression-free survival of 94 months and complete metabolic response on PET scan. This case underscores the importance of molecular profiling in guiding treatment decisions and highlights the efficacy of targeted therapies for ROS1-positive NSCLC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Respirology Case Reports RESPIRATORY SYSTEM-

CiteScore

1.40

自引率

0.00%

发文量

178

审稿时长

8 weeks

期刊介绍： Respirology Case Reports is an open-access online journal dedicated to the publication of original clinical case reports, case series, clinical images and clinical videos in all fields of respiratory medicine. The Journal encourages the international exchange between clinicians and researchers of experiences in diagnosing and treating uncommon diseases or diseases with unusual presentations. All manuscripts are peer-reviewed through a streamlined process that aims at providing a rapid turnaround time from submission to publication.